Esomeprazole Trihydrate 40mg + Domperidone 30mg SR Capsules

Gastroesophageal reflux disease (GERD) and severe acid peptic disorders are frequently complicated by delayed gastric emptying and impaired gastrointestinal motility. Esomeprazole Trihydrate 40mg + Domperidone 30mg Sustained-Release (SR) Capsules offer a highly effective, dual-action therapeutic system designed to manage both excess acid production and underlying motility issues in a single daily dose.

The Synergy of Two Active Ingredients

This combination capsule acts on two distinct biological pathways simultaneously to restore upper gastrointestinal balance:

Esomeprazole Trihydrate (40mg – Immediate/Delayed Release): As a highly potent proton pump inhibitor (PPI), esomeprazole is the pure S-isomer of omeprazole. It provides superior, sustained control over gastric acid secretion by irreversibly blocking the $H^+/K^+$-ATPase enzyme system (the acid pumps) in the gastric parietal cells.
Domperidone (30mg – Sustained Release): Operating as a peripheral dopamine receptor ($D_2$) antagonist, domperidone functions as a prokinetic and antiemetic agent. The sustained-release formulation ensures a steady release of the drug to increase lower esophageal sphincter tone, accelerate gastric emptying, and prevent the upward backflow of acid into the esophagus.

Advanced Multi-Particulate Pellet Technology

To ensure maximum biological efficacy and prevent chemical degradation, Item 9 is manufactured using advanced multi-particulate pellet technology inside a single hard gelatin capsule shell:

Enteric-Coated Esomeprazole Pellets: Because esomeprazole is acid-labile and degrades quickly in the stomach, its pellets are medkinglifescience.com shielded with a specialized enteric polymer coating. These pellets pass safely through the stomach and dissolve rapidly in the alkaline environment of the duodenum for optimal systemic absorption.
Sustained-Release Domperidone Pellets: These pellets are formulated with a time-dependent matrix coating. Instead of releasing the entire dose at once, they release domperidone gradually over several hours, ensuring round-the-clock prokinetic coverage and improved patient compliance.

Primary Clinical Indications

This formulation is widely prescribed for the management of complex upper gastrointestinal conditions, including:

Gastroesophageal Reflux Disease (GERD): Refractory heart burn and acid regurgitation that do not respond to PPI monotherapy alone.
Non-Ulcer Dyspepsia: Chronic indigestion characterized by upper abdominal pain, early satiety, bloating, and nausea.
Gastric and Duodenal Ulcers: Healing and prevention of ulcers aggravated by delayed stomach emptying or acid reflux.

Administration Guidelines

For optimal clinical outcomes, this capsule should be taken once daily in the morning, approximately 30 to 60 minutes before breakfast. Taking it on an empty stomach ensures that the prokinetic agent can optimize gut motility and the PPI can inhibit acid pumps right as they are stimulated by the morning meal.